Dec 07, 2020 / 09:00PM GMT
Operator
Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics ASH AUTO1 and AUTO3 Data Update. As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Dr. Lucinda Crabtree, Vice President, Investor Relations. Please go ahead.
Lucinda Crabtree - Autolus Therapeutics plc - VP of IR & Corporate Communications
Thank you. Good morning or good afternoon, everyone, and thank you for taking part in today's call on the ASH AUTO1 and AUTO3 Data Update. I am Lucinda Crabtree, Vice President of Investor Relations.
With me today are Dr. Christian Itin, our Chairman and Chief Executive Officer; Dr. Robert Chen, our AUTO3 and lymphoma program lead; Dr. Nushmia Khokhar, our Head of Clinical Development; Brent Rice, our Chief Commercial Officer; Dr. Martin Pulé, our Chief Scientific Officer; and Andrew Oakley, our Chief Financial Officer.
Before we begin, I would like to remind you that during today's call, our discussion will contain forward-looking statements. All statements,
Autolus Therapeutics plc - Special Call Transcript
Dec 08, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers